Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
NCT02555371
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
306
Enrollment
INDUSTRY
Sponsor class
Conditions
Asthma
Interventions
BIOLOGICAL:
Mepolizumab 100mg
DRUG:
Placebo
Sponsor
GlaxoSmithKline